Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

DMO

- PMLiVE

Novartis to expand cardiovascular pipeline with $3.1bn Anthos acquisition

The deal includes a candidate in phase 3 development to prevent complications of atrial fibrillation

- PMLiVE

Roche announces positive late-stage results for Gazyva/Gazyvaro in lupus nephritis

The disease affects approximately 1.7 million people worldwide and primarily impacts women

- PMLiVE

Novartis’ Kisqali granted MHRA approval to treat early breast cancer patients

The drug is already approved in the UK to treat advanced cases of the disease

- PMLiVE

Roche shares positive overall survival results for Itovebi in advanced breast cancer

Approximately 56,800 new cases of breast cancer are diagnosed in the UK every year

Bayer symbol

Bayer UK launches digital educational hub to improve menopause support

An estimated 13 million women in the UK are currently perimenopausal or menopausal

- PMLiVE

Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy

The muscle-wasting disorder is estimated to affect one in every 5,000 male births worldwide

Bayer symbol

Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

- PMLiVE

Roche gains rights to Innovent Biologics’ ADC candidate in deal worth over $1bn

IBI3009 targets an antigen significantly overexpressed in cancers including small cell lung cancer

- PMLiVE

Novartis’ investigational spinal muscular atrophy gene therapy shows promise in late-stage study

An estimated one in 10,000 infants globally are affected by the rare neuromuscular disease

- PMLiVE

Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma

Approximately 160,000 cases of the aggressive blood cancer are diagnosed globally every year

- PMLiVE

Novartis gains rights to PTC’s Huntington’s programme in deal worth up to $2.9bn

The genetic disorder affects one in every 10,000 to 20,000 people in the US

- PMLiVE

Novartis’ Kisqali receives EC approval to treat early breast cancer patients

Approximately 70% of breast cancer cases are diagnosed in the early stages of the disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links